Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analys... by Rodrigo Motta-Guerrero, Alejandro Leon Garrido-Lecca, Virgilio E. Failoc-Rojas, Virgilio E. Failoc-Rojas, Ana Calle-Villavicencio, Robert Villacorta-Carranza, Yesenia Huerta-Collado, Alicia Torres-Mera, Mario J. Valladares-Garrido, Víctor Rivera-Francia, Carlos Carracedo, Luis Raez

“…However, the combination of angiogenesis inhibitors and TKI has produced discordant results. …”
Get full text

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer by N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi

“…Irinotecan with fluoropyrimidines is own of the second line chemotherapy options for these patients. As angiogenesis inhibitors can enhance the efficacy of chemotherapy, we investigated the combination of irinotecan and fluoropyrimidines with ramucirumab in metastatic GC.Methods: Eligible patients had advanced morphologically verified GC and disease progression during or within 4 months following first-line therapy. …”
Get full text

Tips and Tricks and Clinical Outcome of Cryopreserved Human Amniotic Membrane Application for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Pilot Study by Stéphane Odet, Christophe Meyer, Christophe Meyer, Camille Gaudet, Elise Weber, Julie Quenot, Stéphane Derruau, Stéphane Derruau, Sebastien Laurence, Sebastien Laurence, Lisa Bompy, Marine Girodon, Brice Chatelain, Cédric Mauprivez, Cédric Mauprivez, Cédric Mauprivez, Esteban Brenet, Halima Kerdjoudj, Halima Kerdjoudj, Narcisse Zwetyenga, Philippe Marchetti, Philippe Marchetti, Anne-Sophie Hatzfeld, Anne-Sophie Hatzfeld, David Toubeau, Fabienne Pouthier, Fabienne Pouthier, Xavier Lafarge, Xavier Lafarge, Heinz Redl, Heinz Redl, Mathilde Fenelon, Mathilde Fenelon, Jean-Christophe Fricain, Jean-Christophe Fricain, Roberta Di Pietro, Roberta Di Pietro, Charlotte Ledouble, Charlotte Ledouble, Charlotte Ledouble, Thomas Gualdi, Anne-Laure Parmentier, Aurélien Louvrier, Aurélien Louvrier, Florelle Gindraux, Florelle Gindraux

“…Medication-related osteonecrosis of the jaw (MRONJ) is a complication of certain pharmacological treatments such as bisphosphonates, denosumab, and angiogenesis inhibitors. There are currently no guidelines on its management, particularly in advanced stages. …”
Get full text

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and netwo... by Wei Chen, Julian Miao, Ying Wang, Wenzhong Xing, Xiumei Xu, Rui Wu

“…Treatment regimens involved in the included studies included first, second, and third-generation tyrosine kinase inhibitors (TKIs), TKIs plus chemotherapy, TKIs plus angiogenesis inhibitors, and platinum-containing doublet chemotherapy with or without bevacizumab. …”
Get full text